We are live on ! Find out more

Structure Therapeutics

GPCR

Market cap $1.76B

24.67 USD

-0.87

3.41%

At close Updated Oct 12, 12:40 PM EDT

1 day

-3.41%

5 days

-10.45%

1 month

-35.82%

3 months

-52.23%

6 months

-54.53%

Year to date

-63.78%

1 year

-18.28%

5 years

-5.12%

10 years

-5.12%

About: Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Employees: 281

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 60%

Neutral 40%

Negative 0%

Zacks Investment Research

LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?

LLY's GLP-1 momentum, Foundayo launch and retatrutide pipeline support growth, but premium valuation and rising competition weigh on the stock.

LLY Stock Down Around 7% in a Month: Buy the Dip or Stay Cautious?

Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Structure Therapeutics Inc. (GPCR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Structure Therapeutics: The Amylin Data Changes The Math

Structure Therapeutics remains a Strong Buy, with recent data de-risking its lead oral obesity drug, aleniglipron. Aleniglipron's 72-week open-label data showed 16.2% weight loss, low AE discontinuations, and no DILI, though Phase 3 efficacy and safety monitoring remain key. ACCG-2671, an oral amylin agonist, now has human data and offers potential for combination therapy, further differentiating GPCR's pipeline.

Structure Therapeutics: The Amylin Data Changes The Math

Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management Transcript

Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management Transcript

Structure Therapeutics Inc. (GPCR) Discusses Positive Clinical Data Updates for Oral Small Molecule Amylin and GLP-1 Programs in Chronic Weight Management Transcript

Zacks Investment Research

Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study

NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.

Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence of target engagement including up to 3.3% body weight loss in Phase 1/2a SAD clinical trial First participants dosed with ACCG-2671 in the 12-week MAD portion of the Phase 1/2a clinical trial; topline data expected in 1H 2027 Aleniglipron (oral small molecule selective GLP-1 receptor agonist) demonstrated up to 16.2% mean reduction in body weight at 72 weeks with no observed plateau, and improved tolerability with a 2.5 mg starting dose, including less than 5% study-drug discontinuation rates due to adverse events in the ACCESS OLE clinical trial ACCOMPLISH-1 and ACCOMPLISH-2 registrational Phase 3 clinical trials for aleniglipron enrollment ongoing; topline data expected in 2H 2028 Company to host conference call today at 8:30 a.m. ET SAN FRANCISCO, Sept.

Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in three upcoming healthcare conferences in September: 2026 Cantor Global Healthcare Conference Date: Thursday, September 10Format: Fireside chat and 1x1 meetingsTime: 3:55 – 4:25 PM EDTLocation: New York, NY Morgan Stanley 24 th Annual Global Healthcare Conference Date: Wednesday, September 16Format: Fireside chat and 1x1 meetingsTime: 10:45 – 11:20 AM EDTLocation: New York, NY Bernstein's 3rd Annual Healthcare Forum Date: Wednesday, September 23Format: Fireside Chat and 1x1 meetingsTime: 3:00 – 3:40 PM EDTLocation: New York, NY The live and archived webcasts will be accessible from the company's website at https://ir.structuretx.com/events-presentations/events and replays will be available for at least 90 days.

Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences

Zacks Investment Research

NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?

Novo Nordisk and Structure Therapeutics are taking different paths in the obesity market, from a global GLP-1 leader to a clinical-stage challenger with oral therapies.

NVO vs. GPCR: Which Obesity Stock Is the Better Buy Right Now?

Structure Therapeutics: A Strong Bet For An Oral GLP-1 Approval Before 2030

Structure Therapeutics (GPCR) maintains a Buy rating, driven by strong Phase 2b data for its oral GLP-1 candidate aleniglipron targeting obesity. Aleniglipron demonstrated up to 16.2% weight loss at 44 weeks, a favorable discontinuation rate, and is now in Phase 3 studies with pivotal data expected Q4 2028. GPCR's $1.34bn cash position is expected to fund completion of Phase 3, supporting a runway through key value inflection points despite high R&D burn.

Structure Therapeutics: A Strong Bet For An Oral GLP-1 Approval Before 2030

Zacks Investment Research

LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?

Lilly's strong Q2, GLP-1 momentum and broad pipeline support growth, but valuation and rising competition remain key risks.

LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?

See News Rankings

Price charts implemented using Lightweight Charts™